Northwest Biotherapeutics reported $11.39M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Agenus USD -199.08M 22.15M Jun/2026
AstraZeneca USD 11.55B 674M Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Celldex Therapeutics USD 649.47M 65.1M Sep/2026
Eisai JPY 209.6B 6.14B Jun/2026
Merck USD 10.75B 5.02B Sep/2026
Northwest Biotherapeutics USD 11.39M 120.04M Mar/2026
Pfizer USD 89B 3.81B Sep/2026
Plus Therapeutics USD 8.15M 1.04M Mar/2026
Roche Holding CHF 18.9B 2.12B Jun/2026